Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a relatively new type of medication developed to treat type 2 diabetes.
Recently, there has been growing evidence that these drugs may provide additional health benefits beyond just controlling blood sugar levels in patients with type 2 diabetes.
Comparing SGLT2 Inhibitors and DPP4 Inhibitors
A study from the University of Hong Kong compared the protective effects on the heart, kidneys, and lungs of SGLT2 inhibitors with those of dipeptidyl peptidase-4 inhibitors (DPP4i), another class of drugs widely used for treating type 2 diabetes.
Kidney Protection
The researchers analyzed data from over 30,000 patients with type 2 diabetes in Hong Kong. They found that SGLT2 inhibitors were strongly linked to lower risks of several kidney diseases, including end-stage renal disease (ESRD).
This suggests that SGLT2 inhibitors may offer additional kidney protective effects in patients with type 2 diabetes, beyond those provided by DPP4 inhibitors.
Respiratory Protection
The study also discovered that SGLT2 inhibitors were associated with reduced risks of several lung diseases, including obstructive airway disease (OAD) and pneumonia.
This is a new finding, as previous studies have mainly focused on the cardiovascular and renal protective effects of SGLT2 inhibitors.
Potential Benefits of SGLT2 Inhibitors
The study suggests that SGLT2 inhibitors may be a better alternative to DPP4 inhibitors for people with type 2 diabetes, as they provide additional protection for the heart, kidneys, and lungs.
These findings highlight the importance of considering all possible treatment options for patients with type 2 diabetes and the potential benefits of SGLT2 inhibitors.
Side Effects
It is important to note that, like all drugs, SGLT2 inhibitors have potential side effects. These include an increased risk of genital and urinary tract infections and a higher risk of diabetic ketoacidosis.
Patients with type 2 diabetes who are considering SGLT2 inhibitors should discuss the potential benefits and risks with their healthcare provider.
Conclusion
This study from the University of Hong Kong provides important real-world evidence that SGLT2 inhibitors may offer additional protection for the heart, kidneys, and lungs in patients with type 2 diabetes compared to DPP4 inhibitors.
These findings highlight the potential benefits of SGLT2 inhibitors and the importance of considering all possible treatment options for patients with type 2 diabetes. Further research is needed to fully understand the mechanisms by which SGLT2 inhibitors provide these protective effects.
If you care about diabetes, please read studies about the sleep problem linked to vision loss in people with diabetes and this drug that may prevent kidney failure in people with diabetes.
For more information about health, please see recent studies that show blueberries strongly benefit people with metabolic syndrome and results showing Vitamin D may reduce dangerous complications in type 2 diabetes.
The study was conducted by Dr. Cheung Ching-lung et al. and published in The Journal of Clinical Endocrinology & Metabolism and JAMA Network Open.
If you care about lung health, please read studies about marijuana’s effects on lung health, and why some non-smokers get lung disease and some heavy smokers do not.
For more information about health, please see recent studies that olive oil may help you live longer, and vitamin D could help lower the risk of autoimmune diseases.
Copyright © 2024 Knowridge Science Report. All rights reserved.
